Key Highlights
- Novo Nordisk introduced a flexible subscription model for Wegovy, featuring 3-, 6-, and 12-month options for cash-paying customers
- Monthly costs for injections span $329 (3-month commitment) to $249 (12-month commitment), representing savings of up to 29% compared to the regular $349 price point
- Pill subscriptions cost between $289 and $249 monthly, offering savings against the standard $299 price
- Current access is available via telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame joining shortly
- Market dynamics show Eli Lilly commanding approximately 60% of U.S. branded GLP-1 sales while Novo captures roughly 39%
Novo Nordisk has unveiled a subscription-based pricing structure for its Wegovy products, marking a strategic push to gain ground in the competitive self-pay obesity treatment segment.
The Copenhagen-based pharmaceutical company rolled out the initiative Tuesday, providing cash-paying customers with fixed monthly pricing through commitment periods of three, six, or twelve months. Extended commitments translate to lower monthly costs.
For injectable Wegovy, pricing breaks down to $329 monthly on three-month subscriptions, $299 for six-month periods, and $249 for annual commitments. These rates represent reductions of up to 29% from the baseline $349 monthly cost.
The Wegovy oral formulation, which entered the U.S. market in January, operates on comparable pricing: $289, $269, or $249 monthly, compared to the standard $299 rate. Annual savings reach $600 for pill subscribers and $1,200 for injection users selecting the longest subscription tier.
Pricing remains consistent regardless of dosage adjustments, eliminating a common source of confusion for self-paying GLP-1 users.
Immediate availability exists through Ro, WeightWatchers, and LifeMD platforms. Additional partners including Hims & Hers and Sesame will join the network shortly. While the company’s proprietary NovoCare pharmacy doesn’t currently offer the program, future expansion remains under consideration.
Strategic Context Behind the Launch
The rollout arrives amid mounting competitive challenges. Eli Lilly dominates approximately 60% of the U.S. branded GLP-1 landscape, leaving Novo with a 39% share. Lilly established direct-to-consumer channels earlier, and its Zepbound medication has demonstrated stronger prescription momentum compared to Wegovy.
Novo has implemented significant organizational changes recently — appointing a new CEO, reducing workforce numbers, and bringing in fresh leadership for its U.S. operations. The subscription program represents another component of this repositioning effort.
The oral Wegovy formulation has attracted patients who previously avoided GLP-1 injections, making the period before Lilly’s competing oral treatment arrives particularly critical. Lilly’s oral obesity medication currently awaits FDA evaluation, with potential authorization anticipated in April.
Industry observers have noted Novo’s vulnerability in pricing competition, pointing to the November reduction of Wegovy injection’s standard self-pay cost from $499 to $349 — a 30% decrease.
Competitive Pricing Landscape
Lilly’s Zepbound self-pay structure begins at $299 monthly for the 2.5mg dosage, $399 for 5mg, and $449 for higher strengths through its “Self Pay Journey Program.”
The subscription model addresses a critical challenge: treatment continuity. Research published in 2025 indicated approximately 65% of obesity patients discontinue GLP-1 therapy within twelve months, frequently citing cost unpredictability and adverse reactions.
Ed Cinca, Novo’s head of marketing and patient solutions, emphasized that subscribers retain cancellation flexibility throughout their active subscription period.
The 4mg Wegovy pill dosage, currently available at $149 monthly, will increase to $199 beginning in September. The recently authorized 7.2mg strength will enter the subscription program at a future date.
